Drug Profile
JNJ 18038683
Alternative Names: JNJ-18038683Latest Information Update: 14 Jul 2023
Price :
$50
*
At a glance
- Originator Janssen Research & Development
- Developer Janssen Research & Development; Northwestern University
- Class Antidepressants; Azepines; Mood stabilisers; Pyrazoles; Small molecules
- Mechanism of Action Serotonin 7 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bipolar disorders
- Discontinued Major depressive disorder
Most Recent Events
- 27 Jun 2019 Chemical structure information added
- 25 Jun 2019 JNJ 18038683 is still in phase II trials for Bipolar disorders in USA (NCT02466685)
- 01 Sep 2015 Phase-II clinical trials in Bipolar disorders in USA (PO) (NCT02466685)